Compare MasterCard Inc (MA) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs Sana Biotechnology Inc — how do they compare? MasterCard Inc trades at $542.08 (market cap $483.71B), while Sana Biotechnology Inc trades at $3.21 (market cap $873.84M). The key difference: MasterCard Inc is far larger — about 553.5× Sana Biotechnology Inc's market cap, and MasterCard Inc pays a 0.64% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| MA | SANA | |
|---|---|---|
Market Cap | $483.71B | $873.84M |
Volume | 4,635,698 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $598.96 | $5.92 |
52-Week Low | $471.55 | $2.68 |
Enterprise Value | $494.45B | $848.03M |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $543.19, down 0.08% on the day, with a bullish technical outlook supported by moving averages and strong institutional buying. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $4.60 exceeding the $4.41 estimate. Revenue grew to $32.79 billion in 2025, while net income margin remained high at 45.88%. Analysts maintain a strong buy consensus with a $634.27 price target, reflecting confidence in continued payment volume growth and digital expansion initiatives.
The stock presents a compelling growth opportunity given its consistent profitability, expanding cash flows, and leadership in digital payments. Key risks include competitive disruption from stablecoins and regulatory scrutiny. With zero sell ratings and 79% buy recommendations, Wall Street sentiment is overwhelmingly positive, though investors should monitor execution on AI and emerging market strategies against valuation multiples above sector averages.
SANA Biotechnology trades at $3.14, down 0.32% with bearish technical indicators despite strong analyst support. The company shows significant financial challenges with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn improved from -$55M to -$12M in 2026. Recent positive developments include a Zacks upgrade to Buy and groundbreaking clinical data published in NEJM.
Investment outlook remains speculative with high execution risk given substantial losses, but strong analyst consensus (82% Buy ratings) reflects optimism about SANA's innovative cell therapy pipeline. Key risks include continued cash burn and clinical trial outcomes, while potential catalysts include successful product development in diabetes and CAR-T therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
